Trade Summary

Yesterday, van Houte Hans, serving as Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,761 shares at $24.36 per share, for a total transaction value of $115,989.47. Following this transaction, van Houte Hans now holds 40,166 shares of NRIX.

This sale represents a 10.60% decrease in van Houte Hans's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 4, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, August 5, 2026 (accepted Aug 4, 9:41 PM ET), 1 day after the trade was made.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.